Human CCL13 (C-C motif chemokine ligand 13), also known as monocyte chemoattractant protein-4 (MCP-4), is a member of the CC chemokine family that plays an important role in leukocyte recruitment and regulation of inflammatory responses. CCL13 is produced by monocytes, macrophages, dendritic cells, epithelial cells, endothelial cells, and fibroblasts in response to pro-inflammatory cytokines such as IL-1β and TNF-α. It functions through chemokine receptors including CCR2, CCR3, and CCR5 to promote chemotaxis and activation of monocytes, eosinophils, basophils, and certain T lymphocyte subsets. In healthy individuals, circulating CCL13 levels are typically low but detectable, and expression increases during inflammatory and allergic conditions. Elevated CCL13 has been associated with asthma, atopic dermatitis, allergic rhinitis, inflammatory bowel disease, rheumatoid arthritis, and certain malignancies, reflecting its role in both Th2-associated and mixed inflammatory responses. In clinical and translational research, human CCL13 serves as a biomarker of immune cell recruitment and inflammatory activation and represents a potential therapeutic target for modulating monocyte- and eosinophil-driven disease processes.